Unknown

Dataset Information

0

Hypoglycemia in CDG patients due to PMM2 mutations: Follow up on hyperinsulinemic patients.


ABSTRACT: Background:Phosphomannomutase 2 deficiency (PMM2-CDG) is the most common congenital disorder of glycosylation (CDG). Hypoglycemia has been reported in various CDG including PMM2-CDG. The frequency and etiology of hypoglycemia in PMM2-CDG are not well studied. Methods:We conducted a systematic review of the literature on genetically and/or biochemically confirmed PMM2-CDG patients who developed hypoglycemia. Prospective follow-up information on the patients who received diazoxide therapy was collected and evaluated. Results:A total of 165 peer-reviewed articles reporting on 933 PMM2-CDG patients were assessed. Hypoglycemia was specifically mentioned only in 23 of these patients (2.5%). Hyperinsulinism was identified in 10 patients (43% of all hypoglycemic patients). Among these 10 patients, seven were successfully treated with diazoxide. However, most patients remained on therapy longer than a year to stay free of hypoglycemia. Conclusion:Hypoglycemia is a rarely reported finding in patients with PMM2-CDG. Diazoxide-responsive hyperinsulinism was found to have a good prognosis on medication in our PMM2-CDG patients with hypoglycemia. No genotype-phenotype correlation was observed with respect to hyperinsulinism. A prospective study should be undertaken to explore the hypothesis that hypoglycemia is underdiagnosed in PMM2-CDG and to evaluate whether hyperinsulinism is always associated with hypoglycemia.

SUBMITTER: Moravej H 

PROVIDER: S-EPMC7012739 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Phosphomannomutase 2 deficiency (PMM2-CDG) is the most common congenital disorder of glycosylation (CDG). Hypoglycemia has been reported in various CDG including PMM2-CDG. The frequency and etiology of hypoglycemia in PMM2-CDG are not well studied.<h4>Methods</h4>We conducted a systematic review of the literature on genetically and/or biochemically confirmed PMM2-CDG patients who developed hypoglycemia. Prospective follow-up information on the patients who received diazoxide t  ...[more]

Similar Datasets

| S-EPMC6454923 | biostudies-literature
| S-EPMC1734666 | biostudies-other
| S-EPMC2857991 | biostudies-literature
| S-EPMC8360885 | biostudies-literature
| S-EPMC4016514 | biostudies-literature
| S-EPMC3509917 | biostudies-literature
| S-EPMC4623922 | biostudies-literature
| S-EPMC6805611 | biostudies-literature
| S-EPMC4488661 | biostudies-literature
| S-EPMC6006654 | biostudies-literature